Literature DB >> 15705618

Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.

Evangelos G Papanikolaou1, Claire Bourgain, Efstratios Kolibianakis, Herman Tournaye, Paul Devroey.   

Abstract

BACKGROUND: Ovarian stimulation for IVF profoundly alters the early luteal phase endometrial development. It has been hypothesized that this process has already started in the late follicular phase, as the endometrium has already been exposed to high steroid concentrations since that phase. The aim of the present study was to prospectively investigate the effect of multi-follicular ovarian stimulation for IVF on the late follicular phase endometrium histology and the expression of estrogen receptor (ER) and progesterone receptor (PR).
METHODS: In a cross-over study, 11 infertile women with normal ovulatory function, participating in an IVF programme and treated with GnRH antagonist/recombinant FSH ovarian stimulation, were enrolled in the study. Endometrial biopsies were taken in a natural cycle on the day of the onset of the surge of the LH, and in a subsequent stimulation cycle on the day of hCG administration for final oocyte maturation. Endometrial histological dating was carried out according to Noyes' criteria. Immunohistochemistry was performed, using commercially available antibodies for ER and PR endometrial expression. The immunohistochemical signal was recorded in 1000 epithelial cells in each compartment (glands and stroma). Endometrial expression for each of the two receptors was graded on a scale of 0-3, based on the intensity of nuclear staining. Then a score range between 0 and 3000 was recorded, and expressed as a mean score per 1000 stroma or glandular cells per sample (range: 0-3).
RESULTS: Histological examination of biopsies both in natural and stimulated cycles showed no secretory changes. However, in stimulated cycles, PR expression was significantly up-regulated compared to natural cycles in both glands (1.67 versus 1.34, P < 0.05) and stroma (1.98 versus 1.62, P < 0.05), whereas ER was down-regulated in glands (1.15 versus 1.43, P < 0.05). In IVF cycles, the progesterone measurements, although within normal values (range 0.8-1.4 microg/l), were significantly higher than in natural cycles (0.99 vs 0.63 microg/l, respectively, P = 0.008). An ongoing pregnancy rate of 37.5% was achieved in the stimulated cycles. DISCUSSION: Although the current study found no early secretory transformation in stimulated endometria before hCG administration, the ER and PR expression in these endometria is similar to the one described during the first days of the luteal phase in natural cycles. Supraphysiological concentrations of estradiol and subtle progesterone rises in the late follicular phase might be responsible for this modulated steroid receptor profile. This phenomenon indicates accentuated maturation of the endometrium in IVF cycles from the pre-ovulatory phase onwards.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705618     DOI: 10.1093/humrep/deh793

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  26 in total

Review 1.  Implantation failure: molecular mechanisms and clinical treatment.

Authors:  Hakan Cakmak; Hugh S Taylor
Journal:  Hum Reprod Update       Date:  2010-08-21       Impact factor: 15.610

Review 2.  The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

Authors:  Mohamed F M Mitwally; Robert F Casper; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-10-04       Impact factor: 5.211

3.  Early pregnancy loss rates were different among singleton gestations conceived by ICSI using GnRH agonist and antagonist.

Authors:  Mustafa Bahceci; Ulun Ulug; Alper Sismanoglu; Suleyman Tosun; Bora Cengiz
Journal:  J Assist Reprod Genet       Date:  2009-03-20       Impact factor: 3.412

Review 4.  Ovarian stimulation for in vitro fertilization alters the protein profile expression in endometrial secretion.

Authors:  Ming-Qing Li; Li-Ping Jin
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

5.  HCG administration after endogenous LH rise negatively influences pregnancy rate in modified natural cycle for frozen-thawed euploid blastocyst transfer: a pilot study.

Authors:  Katarzyna Litwicka; Cecilia Mencacci; Cristiana Arrivi; Maria Teresa Varricchio; Alina Caragia; Maria Giulia Minasi; Ermanno Greco
Journal:  J Assist Reprod Genet       Date:  2017-11-17       Impact factor: 3.412

Review 6.  What is the contribution of embryo-endometrial asynchrony to implantation failure?

Authors:  Wan-Tinn Teh; John McBain; Peter Rogers
Journal:  J Assist Reprod Genet       Date:  2016-08-01       Impact factor: 3.412

7.  Frozen embryo transfer can be performed in the cycle immediately following the freeze-all cycle.

Authors:  Kemal Ozgur; Hasan Bulut; Murat Berkkanoglu; Peter Humaidan; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2017-09-22       Impact factor: 3.412

8.  Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles.

Authors:  Laura Detti; Ghassan M Saed; Nicole M Fletcher; Michael L Kruger; Michelle Brossoit; Michael P Diamond
Journal:  Fertil Steril       Date:  2011-01-12       Impact factor: 7.329

9.  Elective cryopreservation of all day 5 blastocysts is more effective than using day 6 blastocysts for improving pregnancy outcome in stimulated cycles.

Authors:  Setsuko Yamamoto; Michiko Umeki; Teruhiro Hamano; Fujiyo Matsusita; Kimiko Kuwahara
Journal:  Reprod Med Biol       Date:  2008-04-17

10.  Higher clinical pregnancy rates from frozen-thawed blastocyst transfers compared to fresh blastocyst transfers: a retrospective matched-cohort study.

Authors:  Kemal Özgür; Murat Berkkanoğlu; Hasan Bulut; Ayhan Isikli; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2015-09-23       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.